PubRank

L Zitvogel

Author PubWeight™ 69.06‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001 5.71
2 Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999 4.92
3 Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol 1999 4.87
4 Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995 3.67
5 Cell death modalities: classification and pathophysiological implications. Cell Death Differ 2007 3.19
6 Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2009 2.74
7 Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 2007 2.58
8 The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 2008 2.01
9 Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2007 1.92
10 Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 2010 1.75
11 Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 2013 1.65
12 Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ 2013 1.64
13 Prospects for exosomes in immunotherapy of cancer. J Cell Mol Med 2006 1.63
14 Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J Clin Invest 1997 1.39
15 Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin. J Exp Med 1996 1.36
16 Tumor-derived exosomes: a new source of tumor rejection antigens. Vaccine 2002 1.33
17 Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995 1.26
18 Reduction of endoplasmic reticulum Ca2+ levels favors plasma membrane surface exposure of calreticulin. Cell Death Differ 2007 1.23
19 Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis 2010 1.18
20 Dendritic cell maturation overrules H-2D-mediated natural killer T (NKT) cell inhibition: critical role for B7 in CD1d-dependent NKT cell interferon gamma production. J Exp Med 2001 1.16
21 Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. Cell Death Differ 2013 1.13
22 Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ 2013 1.12
23 Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. Blood Cells Mol Dis 2005 1.04
24 Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 1997 1.04
25 Exosomes for cancer immunotherapy. Ann Oncol 2004 1.03
26 The Janus face of dendritic cells in cancer. Oncogene 2008 1.03
27 Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells. J Immunol 2001 1.02
28 Tumor stress, cell death and the ensuing immune response. Cell Death Differ 2007 1.01
29 Interleukin-7 (IL-7) in colorectal cancer: IL-7 is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes. Scand J Immunol 1997 1.00
30 Dendritic cells in innate immune responses against HIV. Curr Mol Med 2002 1.00
31 Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. Cancer Gene Ther 1998 0.99
32 Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. Ann N Y Acad Sci 1996 0.98
33 Viral strategies for the evasion of immunogenic cell death. J Intern Med 2010 0.96
34 Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines. Cell Death Differ 2013 0.95
35 Exosomes for the treatment of human malignancies. Horm Metab Res 2008 0.90
36 The immune response against dying tumor cells: avoid disaster, achieve cure. Cell Death Differ 2008 0.87
37 Human intestinal V delta 1+ T cells obtained from patients with colon cancer respond exclusively to SEB but not to SEA. Nat Immun 1995 0.87
38 IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum Gene Ther 1995 0.85
39 Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects. Cytokines Cell Mol Ther 1998 0.84
40 Exosomes in cancer immunotherapy: preclinical data. Adv Exp Med Biol 2001 0.84
41 Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice. Laryngoscope 1998 0.80
42 Killer dendritic cells and their potential role in immunotherapy. Horm Metab Res 2008 0.80
43 Murine models of cancer cytokine gene therapy using interleukin-12. Ann N Y Acad Sci 1996 0.78
44 Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12). J Immunother 2000 0.78
45 Cancer is not just a disease of a tissue: it is a host disease. How to reactivate host defense against tumors using conventional therapies of cancer? Ann Endocrinol (Paris) 2008 0.76
46 [Antitumor cellular immunotherapy: the breakthrough of dendritic cells]. Bull Cancer 2000 0.75
47 Retroviral vectors for use in human gene therapy for cancer, Gaucher disease, and arthritis. Ann N Y Acad Sci 1994 0.75
48 [Role of dendritic cells in the modulation of innate effectors of immunity]. Pathol Biol (Paris) 2001 0.75